Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine

Life Sciences

Volumn 81, Issue 2, 2007, Pages 121-127

  Bolayirli, Ibrahim Murat ^a   Aslan, Mahmure ^a   Balci, Huriye ^a   Altug, Tuncay ^a   Hacibekiroglu, Munire ^a   Seven, Arzu ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

ADMA; Homocysteine; Hypercholesterolemia; Oxidative stress; PON1

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME ACTIVITY; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; OXIDATIVE STRESS; RABBIT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ARGININE; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIET; HEPTANOIC ACIDS; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID PEROXIDATION; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDATIVE STRESS; PYRROLES; RABBITS; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TRIGLYCERIDES;

ORYCTOLAGUS CUNICULUS;

EID: 34250329234     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2007.04.027     Document Type: Article

References (50)

1. Al-Zuhair H., Abd el-Fattah A.A., and Abd el Latif H.A. Efficacy of simvastatin and pumpkin-seed oil in the management of dietary-induced hypercholesterolemia. Pharmacological Research 35 5 (1997) 403-408
2. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., and La Du B. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Biology & Medicine 26 7-8 (1999) 892-904
3. Buege J.A., and Aust S.D. Microsomal lipid peroxidation. Methods in Enzymology 52 (1978) 302-310
4. Bode-Böger S.M., Böger R.H., Kienke S., Junker W., and Frölich J.C. Elevated l-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary l-arginine in hypercholesterolemic rabbits. Biochemical and Biophysical Research Communications 219 (1996) 598-603
5. Böger R.H. Association of asymmetric dimethylarginine and endothelial dysfunction. Clinical Chemistry and Laboratory Medicine 41 (2003) 1467-1472
6. Böger R.H. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovascular Research 59 (2003) 824-833
7. Böger R.H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the 'l-arginine paradox' and acts as a novel cardiovascular risk factor. Nutrition 134 (2004) 2842-2847
8. Böger R.H., Bode-Boger S.M., Brandes R.P., Phivthong-ngam L., Bohme M., Nafe R., Mugge A., and Frolich J.C. Dietary l-arginine reduces the progression of atherosclerosis in cholesterol fed rabbits. Circulation 96 (1997) 1282-1290
9. Böger R.H., Lentz S., Bode-Böger S.M., Knapp H.R., and Haynes W.G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocysteinaemia in humans. Clinical Science 100 (2001) 161-167
10. Cooke J.P. Does ADMA cause endothelial dysfunction?. Arteriosclerosis, Thrombosis and Vascular Biology 20 (2000) 2032-2037
11. De Lorgeril M., Salen P., Paillard F., Lacan P., and Richard G. Lipid-lowering drugs and homocysteine. Lancet 353 (1999) 209-210
12. El-Saadani M., Esterbauer H., and El-Sayed M. A spectrophotometric assay of lipid peroxides in serum lipoproteins using a commercially available reagent. Journal of Lipid Research 30 4 (1989) 627-631
13. Ferretti G., Bacchetti T., Marotti E., and Curatola G. Effect of homocysteinylation on human high density lipoproteins: a correlation with paraoxonase activity. Metabolism 52 2 (2003) 146-151
14. Fuhrman B., Koren L., Volkova N., Keidar S., Hayek T., and Aviram M. Atorvastatin therapy in hypercholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating monocytes. Atherosclerosis 164 (2002) 179-185
15. Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J., and Turpin G. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in mixed hyperlipidemia. Atherosclerosis 154 (2001) 421-427
16. Gorog P., Kotak D.C., and Kovacs I.B. Simple and specific test for measuring lipid peroxides in plasma. Journal of Clinical Pathology 44 (1991) 765-767
17. Harangi M., Seres I., Varga Z., Emri G., Szilvassy Z., Paragh G., and Remenyik E. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. European Journal of Clinical Pharmacology 60 10 (2004) 685-691
18. Hasselwander O., Savage D.A., McMaster D., Loughrey C.M., McNamee P.T., Middleton D., Nicholls D.P., Maxwell A.P., and Young I.S. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney International 56 1 (1999) 289-298
19. Hayashi T., Rani J.A., Fukatsu A., Matsui-Hirai H., Osawa M., Miyazaki A., Tsunekawa T., Kano-Hayashi H., Iguchi A., Sumi D., and Ignarro L.J. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis 176 2 (2004) 255-263
20. Herdeg C., Fitzke M., Oberhoff A., Schroeder S., and Karsch K.R. Effects of atorvastatin on in-stent stenosis in normo- and hypercholesterolemic rabbits. International Journal of Cardiology 91 (2003) 59-69
21. Hong S.C., Zhao S.P., and Wu Z.H. Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. Journal of Cardiovascular Pharmacology 47 1 (2006) 77-81
22. Ito A., Tsao P.S., Adimoolam S., Kimoto M., Ogawa T., and Cooke J.P. Novel mechanism for endothelial dysfunction dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99 (1999) 3092-3095
23. Jacobs M., Plane F., and Bruckdorfer K.R. Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. British Journal of Pharmacology 100 1 (1990) 21-26
24. Jakubowski H. Homocysteine-thiolactone and S-nitroso-homocysteine mediate incorporation of homocysteine into protein in humans. Clinical Chemistry and Laboratory Medicine 41 11 (2003) 1462-1466
25. Kielstein J.T., Bode-Boger S.M., Klein G., Graf S., Haller H., and Fliser D. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. European Journal of Clinical Investigation 33 (2003) 370-375
26. Kural B.V., Orem C., Uydu H.A., Alver A., and Orem A. The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia. Coronary Artery Disease 15 5 (2004) 277-283
27. Liao J.K., Shin W.S., and Lee W.Y. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. The Journal of Biological Chemistry 270 (1995) 319-324
28. Liu B.W., Jiang Y., Fu M.D., Liu Y., and Fan P. Oxidative modification of lipoproteins in hypertriglyceridemic patients and hypercholesterolemic rabbits in vivo. Molecular and Cellular Biochemistry 207 (2000) 131-135
29. Lu T., Ding Y., Leu H., Yin W., Sheu W., and Chu K. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. The American Journal of Cardiology 94 (2004) 157-161
30. Ma L.P., Kang M.F., Yin S.M., Nie D.N., Xie S.F., Wu Y.D., Li Y.Q., Feng J.H., and Xu L.Z. The effects of pravastatin on platelet derived nitric oxide system in rabbits. Zhonghua Xue Ye Xue Za Zhi 26 9 (2005) 539-542
31. Mügge A., Hanefeld C., and Boger R.H. Plasma concentration of asymmetric dimethyl arginine and risk of coronary heart disease: rationale and design of the multicenter CARDIAC study. Atherosclerosis. Supplements 4 (2003) 29-32
32. Paiva H., Laakso J., Lehtimaki T., Isomustajarvi M., Ruokenen I., and Laksonen R. Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. Journal of Cardiovascular Pharmacology 41 2 (2003) 219-222
33. Paragh G., Toroscsik D., Seres I., Harangi M., Illyes L., Balogh Z., and Kovacs P. Effect of short term treatment with simvastatin and atorvastatin on lipids and paraoxonase activity in patients with hyperlipoproteinemia. Current Medical Research and Opinion 20 8 (2004) 1321-1327
34. Prasad K. Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside isolated from flaxseed. Circulation 99 (1999) 1355-1362
35. Prasad K. Hypocholesterolemic and antiatherosclerotic effect of flax lignan complex isolated from flaxseed. Atherosclerosis 179 2 (2005) 269-275
36. Rajamannan N.M., Subramaniam M., Stock S.R., Stone N.J., Springett M., Ignatiev K.I., McConnell J.P., Singh R.J., Bonow R.O., and Spelsberg T.C. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 91 6 (2005) 806-810
37. Rasmusen C., Cynober L., and Couderc R. Arginine and statins: relationship between the nitric oxide pathway and the atherosclerosis development. Annales de Biologie Clinique 63 5 (2005) 443-455
38. Rosenblat M., Hayek T., Hussein K., and Aviram M. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arteriosclerosis, Thrombosis and Vascular Biology 24 (2004) 175-180
39. Shai I., Stampfer M., Ma J., Manson J.E., Hankinson S.E., Cannussio C., Selhub J., Curhan G., and Rimm E.B. Homocysteine as a risk factor for a coronary heart diseases and its association with inflammatory biomarkers, lipids and dietary factors. Atherosclerosis 177 2 (2004) 375-381
40. Stühlinger M.C., Tsao P.S., Her J.H., Kimoto M., Balint R.F., and Cooke J.P. Homocysteine impairs the nitric oxide synthase pathway role of asymmetric dimethylarginine. Circulation 104 (2001) 2569-2575
41. Stühlinger M.C., Oka R.K., Graf E.E., Schmolzer I., Upson B.M., Kapoor O., Szuba A., Malinow M.R., Wascher T.C., Pachinger O., and Cooke J.P. Endothelial dysfunction induced by hyperhomocysteinemia role of asymmetric dimethylarginine. Circulation 108 8 (2003) 933-938
42. Szilvassy Z., Csont T., Pali T., Droy-Lefaix M.T., and Ferdinandy P. Nitric oxide, peroxynitrite and cGMP in atherosclerosis-induced hypertension in rabbits: beneficial effects of cicletanine. Journal of Vascular Research 38 1 (2001) 39-46
43. Tomas M., Senti M., Faria F.G., Vila J., Torrents A., Covas M., and Marrugat J. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arteriosclerosis, Thrombosis and Vascular Biology 20 9 (2000) 2113-2119
44. Tsimihodimos V., Karabina S.A.P., and Tambaki A.P. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arteriosclerosis, Thrombosis and Vascular Biology 22 (2002) 306-311
45. Valkonen V.P., Laakso J., Paiva H., Lehtimaki T., Lakka T.A., Isomustajarvi M., Ruokonen I., Salonen J.T., and Laaksonen R. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA level?. Atherosclerosis Supplements 4 4 (2003) 19-22
46. Van Nieuw Amerongen G.P., Vermeer M., Negre-Aminou P., Lankelma J., Emeis J.J., and Van Hinsbergh V. Simvastatin improves disturbed endothelial barrier function. Circulation 102 23 (2000) 2803-2809
47. Wang J., Sim A.S., Wang X.L., Salonikas C., Naidoo D., and Wilcken D.E.L. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 184 (2006) 383-388
48. Yoo J.H., and Lee S.C. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 158 (2001) 425-430
49. Zhao S., Wu Z., Hong S., Ye H., and Wu J. Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol efflux in adipocytes of hypercholesterolemic rabbits. Clinica Chimica Acta 365 (2006) 119-124
50. Zulli A., Hare D.L., Buxton B.F., and Black M.J. High dietary methionine plus cholesterol exacerbates atherosclerosis formation in the left main coronary artery of rabbits. Atherosclerosis 176 (2004) 83-89